Recorded fact · drug.label_indication
drug.label_indication for levothyroxine-sodium|thyroid-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact c9b5e1b6 resolves to.
The record
| Fact id | c9b5e1b6639f7b178c140a32 |
|---|---|
| Entity | drug: levothyroxine-sodium|thyroid-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:22:03.764Z |
| Source version | openfda-label-20260324 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
oxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: efbac84eae41648ebaf98b90e5fc8a30fdfd528d37e98b95e67bcbc4940fd033.
The value
{
"ingredient": "Levothyroxine Sodium",
"conditionId": "thyroid-cancer",
"conditionName": "Thyroid cancer",
"matchedAlias": "thyroid cancer",
"context": "indication",
"brand": "Levothyroxine sodium",
"identifiedVia": "generic_name",
"extractor": 5,
"labelSetId": "008de8fd-150f-4022-8ccb-c8bfa94875c7",
"labelEffectiveTime": "20260324",
"labelsRead": 19,
"labelsNaming": 18,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 8c10680a6d93aa70fa2b2c8bc9ddf0b16a344c65cf52a94cb8859d4be50d261c.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.